Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion

被引:69
作者
Akpek, G [1 ]
Boitnott, JK [1 ]
Lee, LA [1 ]
Hallick, JP [1 ]
Torbenson, M [1 ]
Jacobsohn, DA [1 ]
Arai, S [1 ]
Anders, V [1 ]
Vogelsang, GB [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol Pathol & Med, Baltimore, MD 21231 USA
关键词
D O I
10.1182/blood-2002-03-0857
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Graft-versus-host disease (GVHD) of the liver is characterized by bile duct damage and portal lymphocytic infiltrate. We report acute hepatitislike presentation of GVHD after donor lymphocyte infusion (DLI). Between April 1998 and September 2001, 73 patients received 94 DLI treatments. Liver GVHD developed after DLI in 22 (30%) patients whose median age was 43 years (range, 21 to 61 years). Onset of liver dysfunction was at 35 days (range, 11 to 406 days) after DLI. Fifteen patients underwent liver biopsy, and the diagnosis of liver GVHD was confirmed in 13 (87%) patients. After viral hepatitis and recent drug exposure were excluded, 11 (50%) patients were given a diagnosis of a hepatitic variant of GVHD based on histologic evidence of lobular hepatitis (n = 5), elevation of maximum serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level more than 10 times the upper normal limit (n = 9), or both. There was a significant difference in maximum ALT (P = .002) and AST (P = .01) level between the hepatitic-variant and classical GVHD groups. GVHD progressed in 14 (64%) patients, and 10 patients died after a median follow-up of 221 days (range, 31-1284 days). These observations suggest that GVHD that occurs after DLI may have distinct clinical features. Hepatitic-variant GVHD should be considered in the differential diagnosis in DLI recipients with unexplained hepatitis. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:3903 / 3907
页数:5
相关论文
共 24 条
[11]  
Malik AH, 2001, AM J GASTROENTEROL, V96, P588
[12]   A RETROSPECTIVE ANALYSIS OF THERAPY FOR ACUTE GRAFT-VERSUS-HOST DISEASE - INITIAL TREATMENT [J].
MARTIN, PJ ;
SCHOCH, G ;
FISHER, L ;
BYERS, V ;
ANASETTI, C ;
APPELBAUM, FR ;
BEATTY, PG ;
DONEY, K ;
MCDONALD, GB ;
SANDERS, JE ;
SULLIVAN, KM ;
STORB, R ;
THOMAS, ED ;
WITHERSPOON, RP ;
LOMEN, P ;
HANNIGAN, J ;
HANSEN, JA .
BLOOD, 1990, 76 (08) :1464-1472
[13]  
MARTIN PJ, 1991, BLOOD, V77, P1821
[14]   INTESTINAL AND HEPATIC COMPLICATIONS OF HUMAN-BONE MARROW TRANSPLANTATION .1. [J].
MCDONALD, GB ;
SHULMAN, HM ;
SULLIVAN, KM ;
SPENCER, GD .
GASTROENTEROLOGY, 1986, 90 (02) :460-477
[15]   Active participation of CCR5+CD8+ T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease [J].
Murai, M ;
Yoneyama, H ;
Harada, A ;
Yi, Z ;
Vestergaard, C ;
Guo, BY ;
Suzuki, K ;
Asakura, H ;
Matsushima, K .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (01) :49-57
[16]  
Serody JS, 2000, BLOOD, V96, P2973
[17]   A CODED HISTOLOGIC-STUDY OF HEPATIC GRAFT-VERSUS-HOST DISEASE AFTER HUMAN-BONE MARROW TRANSPLANTATION [J].
SHULMAN, HM ;
SHARMA, P ;
AMOS, D ;
FENSTER, LF ;
MCDONALD, GB .
HEPATOLOGY, 1988, 8 (03) :463-470
[18]   Myositis, polyserositis with a large pericardial effusion and constrictive pericarditis as manifestations of chronic graft-versus-host disease after non-myeloablative peripheral stem cell transplantation and subsequent donor lymphocyte infusion [J].
Silberstein, L ;
Davies, A ;
Kelsey, S ;
Foran, J ;
Murrell, C ;
D'Cruz, D ;
Vinnicombe, S ;
Norton, A ;
Cavenagh, J .
BONE MARROW TRANSPLANTATION, 2001, 27 (02) :231-233
[19]   HEPATIC GRAFT VERSUS HOST-DISEASE - A STUDY OF THE PREDICTIVE VALUE OF LIVER-BIOPSY IN DIAGNOSIS [J].
SNOVER, DC ;
WEISDORF, SA ;
RAMSAY, NK ;
MCGLAVE, P ;
KERSEY, JH .
HEPATOLOGY, 1984, 4 (01) :123-130
[20]  
Strasser S, 1999, HEMATOPOIETIC CELL T, P627